OBIO — Orchestra BioMed Holdings, Inc.

OBIO

SHORT CANDIDATEMeanRev

Composite

28.80

Technical

82.40

Fundamental

11.00

Rank

—

Price

6.01

Hurst

0.38

As of

Nov 12, 2026

Daily

Orchestra BioMed Holdings, Inc.

HealthcareBiotechnology

Orchestra BioMed develops therapeutic devices across multiple treatment areas in the United States. Its pipeline includes bioelectronic therapies targeting hypertension and heart failure, an drug-coated balloon for arterial disease, specialized surgical instruments, and an endoscopy cleaning system. The company has partnerships with Medtronic and Terumo to advance its vascular and cardiac device candidates.

Market cap

$570.6M

P/E (trailing)

—

P/E (forward)

-4.92

PEG ratio

—

Dividend yield

0.00%

Beta

0.55

52w range

3.46 – 7.37

Return on equity

-182.29%

Profit margin

-182.50%

Revenue growth

-89.40%

Earnings growth

—

Price history

1Y: 7.25 (+84.0%) · range 3.49–7.25

Cycle position

69/ 100 cycle scoreAPPROACHING EXIT

ENTRYAPPROACHMID-BULLNEAR-TOPEXIT

entry readiness 5 · NOT READY · exit proximity 70

Conviction

21/ 100 · maturity 43%

VScore.2217

Buildup.2654

EMA entry setup.325

Fundamentals.1911

Volume profile

POC

3.97

Price vs POC

+82.4%

Overhead supply

Runway

open sky

Value area 3.56–5.84 · 0% of 120d volume overhead · clean runway

Get an AI analyst's read on this ticker.Open the AI analyst

Contributing sources

Source	Score	Last seen
earnings-surprise	0.900	Nov 13, 2026

Forward returns

Not yet labeled — the study prices these as positions mature.